Seer, Inc. is a life sciences company. It is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcher’s laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. It has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument.
Growing
The company is in a growing phase, with the latest annual income totaling USD 16.58M.
Fairly Valued
The company’s latest PB is 0.38, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 29.42M shares, decreasing 20.92% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 13.17K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.45.